Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Pharmacokinetics and pharmacodynamics of insulin aspart in patients with type 2 diabetes: assessment using a meal tolerance test under clinical conditions.
Ando H, Kurita S, Shimizu A, Kato K, Ishikura K, Taji K, Uno M, Takeshita Y, Misu H, Fujimura A, Kaneko S, Takamura T.
Clin Exp Pharmacol Physiol. 2012 Jun;39(6):528-34. doi: 10.1111/j.1440-1681.2012.05708.x.
Similar articles
Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
Jovanovic L, Giammattei J, Acquistapace M, Bornstein K, Sommermann E, Pettitt DJ.
Clin Ther. 2004 Sep;26(9):1492-7.
Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial.
Perriello G, Pampanelli S, Porcellati F, Avogaro A, Bosi E, Petrella G, Squatrito S, Furneri S, Marra G, Vitali L, Previti M, Cucinotta D.
Diabet Med. 2005 May;22(5):606-11.
Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
Hermansen K, Colombo M, Storgaard H, ØStergaard A, Kølendorf K, Madsbad S.
Diabetes Care. 2002 May;25(5):883-8.
The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences.
Home PD.
Diabetes Obes Metab. 2012 Sep;14(9):780-8. doi: 10.1111/j.1463-1326.2012.01580.x. Epub 2012 Mar 9. Review.
Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B.
Clin Ther. 2009 May;31(5):980-7. doi: 10.1016/j.clinthera.2009.05.010.
Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes.
Lindholm A, McEwen J, Riis AP.
Diabetes Care. 1999 May;22(5):801-5.
A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study.
Ma Z, Parkner T, Frystyk J, Laursen T, Lauritzen T, Christiansen JS.
Diabetes Technol Ther. 2012 Jul;14(7):589-95. doi: 10.1089/dia.2011.0299. Epub 2012 Apr 20.
Lower incidence of recorded cardiovascular outcomes in patients with type 2 diabetes using insulin aspart vs. those on human regular insulin: observational evidence from general practices.
Rathmann W, Kostev K.
Diabetes Obes Metab. 2013 Apr;15(4):358-63. doi: 10.1111/dom.12035. Epub 2012 Nov 28.
Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes.
Hermansen K, Vaaler S, Madsbad S, Dalgaard M, Zander M, Begtrup K, Soendergaard K.
Metabolism. 2002 Jul;51(7):896-900.
A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes.
Plank J, Wutte A, Brunner G, Siebenhofer A, Semlitsch B, Sommer R, Hirschberger S, Pieber TR.
Diabetes Care. 2002 Nov;25(11):2053-7.
The post-prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart.
Ceriello A, Cavarape A, Martinelli L, Da Ros R, Marra G, Quagliaro L, Piconi L, Assaloni R, Motz E.
Diabet Med. 2004 Feb;21(2):171-5.
Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.
Malone JK, Woodworth JR, Arora V, Yang H, Campaigne BN, Hallé JP, Yale JF, Grossman LD.
Clin Ther. 2000 Feb;22(2):222-30.
Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes.
Gredal C, Rosenfalck A, Dejgaard A, Hilsted J.
Diabetes Res Clin Pract. 2008 May;80(2):293-8. doi: 10.1016/j.diabres.2007.12.023. Epub 2008 Mar 4.
Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.
von Mach MA, Brinkmann C, Hansen T, Weilemann LS, Beyer J.
Exp Clin Endocrinol Diabetes. 2002 Nov;110(8):416-9.
Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.
Heise T, Hövelmann U, Brøndsted L, Adrian CL, Nosek L, Haahr H.
Diabetes Obes Metab. 2015 Jul;17(7):682-8. doi: 10.1111/dom.12468. Epub 2015 May 8.
Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus.
Yoshihara T, Kumashiro N, Kanazawa Y, Mita T, Sakurai Y, Kawai J, Abe M, Motojima K, Hara K, Yamazaki Y, Kanazawa A, Miwa S, Sato F, Kanno R, Shimizu T, Sakai K, Uchino H, Watada H, Tanaka Y, Kawamori R, Hirose T.
Endocr J. 2006 Feb;53(1):67-72.
Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers.
Home PD, Barriocanal L, Lindholm A.
Eur J Clin Pharmacol. 1999 May;55(3):199-203.
A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes.
Bretzel RG, Arnolds S, Medding J, Linn T.
Diabetes Care. 2004 May;27(5):1023-7.
Effects of mealtime insulin aspart and bedtime neutral protamine Hagedorn insulin on postprandial coagulation and fibrinolysis in patients with type 2 diabetes.
Bladbjerg EM, Henriksen JE, Akram S, Gram J.
Diabetes Obes Metab. 2012 May;14(5):447-53. doi: 10.1111/j.1463-1326.2011.01547.x. Epub 2012 Jan 6.
Filters: Manage Filters